Femasys FEMY Insider Ownership

NASDAQ FEMY
$1.67 +0.04 (+2.45%)
At close: Oct 20, 2026 · 4:00 PM EDT

Insider Holdings by Owner

46.19K Shares

Insider Ownership Statistics

as of 30 Sep, 2026
Insider Ownership
1.38%
▲+0.623% pp QoQ
Shares Held by Insiders
46.19K
filed for Sep 2026
▲+82.79% QoQ
Shares Outstanding
3.36Mn
3,357,117 shares
Direct Holdings
46.19K
Indirect: 0
Net Shares Traded (QoQ)
+20.92K
net buying in Sep 2026
Insiders Holding Shares
7
with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding
Latest —
Average ownership —
Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold
Latest quarter —
Net over range —
Buying quarters —

Insider Ownership Summary

Across the past 12 months, open-market trades by Femasys insiders were all purchases, totaling $74,000.

Form 4 Holdings

Insiders Holding FEMY

Insiders 7
Shares held 46.19K
Of outstanding 1.38%
# Insider Position Direct Indirect Total Share of Insiders Last Filed
1 Kathy Lee-Sepsick Chief Executive Officer 15,625 0 15,625 33.8% 11 Aug, 2026
2 Dov Elefant Chief Financial Officer 15,625 0 15,625 33.8% 11 Aug, 2026
3 John Charles Canning Chief Operating Officer 4,375 0 4,375 9.5% 11 Aug, 2026
4 Daniel Scott Currie Chief Operating Officer 4,314 0 4,314 9.3% 04 Jun, 2025
5 Jeffrey Gerald Mifek Chief Clinical Medical Affairs 3,125 0 3,125 6.8% 11 Aug, 2026
6 Jeremy Alexander Sipos Chief Technology Officer 3,125 0 3,125 6.8% 11 Aug, 2026
7 Charles Larsen Director 3 0 3 0.0% 04 Jun, 2025

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

123 Insider Transactions

Source SEC Form 4
Latest quarter Sep 2026
Download Data
Date Insider Position Transaction Shares Price Value Shares Held After Ownership
24 Jun, 2026 Edward R Uzialko Director Acquired A 880 $0.00 $0 880 Direct
07 Aug, 2026 John Charles Canning Chief Operating Officer Acquired P 4,375 $3.20 $14.00K 4,375 Direct
07 Aug, 2026 Jeremy Alexander Sipos Chief Technology Officer Acquired P 3,125 $3.20 $10.00K 3,125 Direct
07 Aug, 2026 Dov Elefant Chief Financial Officer Acquired P 15,625 $3.20 $50.00K 15,625 Direct
07 Aug, 2026 Jeffrey Gerald Mifek Chief Clinical Medical Affairs Acquired P 3,125 $3.20 $10.00K 3,125 Direct
24 Jun, 2026 Alistair Milnes Director Acquired A 880 $0.00 $0 880 Direct
24 Jun, 2026 Charles Larsen Director Acquired A 880 $0.00 $0 880 Direct
06 Jul, 2026 Jeffrey Gerald Mifek Chief Clinical Medical Affairs Acquired A 6,250 $0.00 $0 6,250 Direct
24 Jun, 2026 Kenneth D. Eichenbaum Director Acquired A 880 $0.00 $0 880 Direct
07 Aug, 2026 Kathy Lee-Sepsick Chief Executive Officer Acquired P 15,625 $3.20 $50.00K 15,625 Direct
07 Aug, 2026 John Charles Canning Chief Operating Officer Acquired A 4,375 — — 4,375 Direct
07 Aug, 2026 Kathy Lee-Sepsick Chief Executive Officer Acquired A 15,625 — — 15,625 Direct
07 Aug, 2026 Jeremy Alexander Sipos Chief Technology Officer Acquired A 3,125 — — 3,125 Direct
07 Aug, 2026 Jeffrey Gerald Mifek Chief Clinical Medical Affairs Acquired A 3,125 — — 3,125 Direct
07 Aug, 2026 Dov Elefant Chief Financial Officer Acquired A 15,625 — — 15,625 Direct
07 Aug, 2026 Jeffrey Gerald Mifek Chief Clinical Medical Affairs Acquired A 3,125 — — 3,125 Direct
07 Aug, 2026 Jeremy Alexander Sipos Chief Technology Officer Acquired A 3,125 — — 3,125 Direct
07 Aug, 2026 Dov Elefant Chief Financial Officer Acquired A 15,625 — — 15,625 Direct
07 Aug, 2026 Kathy Lee-Sepsick Chief Executive Officer Acquired A 15,625 — — 15,625 Direct
07 Aug, 2026 John Charles Canning Chief Operating Officer Acquired A 4,375 — — 4,375 Direct